HER2基因扩增的乳腺黏液腺癌基因表达及临床病理学特征

目的探讨HER2基因扩增的乳腺黏液腺癌(mucinous breast carcinoma, MBC)雌激素受体(ER)、孕激素受体(PR)、Ki-67和HER2的表达情况、临床病理特征及淋巴结转移和相关预后情况。方法收集中国医科大学附属盛京医院2015年1月至2021年7月且均已经过病理医师诊断的MBC 47例, 进行荧光原位杂交(FISH)检测, 观察HER2基因扩增情况;回顾性分析47例患者临床病理资料, 并统计HER2扩增/未扩增的MBC中ER、PR、Ki-67和HER2的表达及淋巴结转移情况, 并对符合条件的患者进行随访, 分析相关预后。结果 47例MBC中单纯型乳腺黏液癌(pure mucinous breast carcinoma, PMBC)32例(68.1%)和混合型乳腺黏液癌(mixed mucinous breast carcinoma, MMBC)15例(31.9%), HER2基因扩增的10例(21.3%), 未扩增的37例(78.7%);HER2基因的扩增与否与MBC患者的性别、年龄、组织学类型、肿瘤直径、病灶侧别等差异无统计学意义(P>0.05);H...     

浸润性乳腺Paget病3例并文献复习

目的：探讨浸润性乳腺Paget病(invasive mammary Paget disease,invMPD)的临床病理特征。方法：回顾性分析3例浸润性乳腺Paget病的临床资料和病理资料并复习文献。结果：3例患者均有乳头糜烂,1例伴有乳头溃疡,1例同侧乳腺左侧外上象限浸润性癌,1例伴有同侧乳腺高级别导管内癌。组织学表现为具有典型的乳腺Paget病的特征,可见小的浸润灶突破基底膜,浸润真皮浅层。免疫组织化学示肿瘤细胞均表达ER、CK7、EMA;2例表达PR,2例HER-2(3+),1例HER-2(2+),Ki67从40%~60%;S-100、P63均阴性。结论：浸润性乳腺Paget病是一种罕见的肿瘤,与非浸润性乳腺Paget病(non-invasive mammary Paget disease,non-invMPD)有相似的预后。     

乳腺基底样浸润性小叶癌临床病理分析

目的 探讨乳腺基底样浸润性小叶癌(ILC)的临床病理特点、临床进展及预后.方法 对4例乳腺基底样ILC进行病理形态学观察,并采用MaxVision法进行免疫组织化学E-cadherin、p120 catenin、雌激素受体(ER)、孕激素受体(PR)、HER2、CK5/6、表皮生长因子受体(EGFR)、p63、p53、Ki-67染色,对其进行随访和分析并回顾相关文献.结果 4例乳腺基底样ILC,1例为混合型,3例为多形型.免疫组织化学染色肿瘤细胞3例E-cadherin阴性,1例少部分胞膜阳性;p120 catenin 均为胞质阳性,l例少部分除细胞质阳性外有少部分细胞膜阳性;ER、PR及HER2均呈“三阴性”;CK5/6和EGFR均呈不同程度阳性;p63 2例阳性;p53阳性或弱阳性;Ki-67阳性指数为30％ ～ 75％.2例有腋窝和锁骨下淋巴结转移,3例获得随访,其中2例发生胸壁转移,1例同时发生肝转移和腹部转移.结论 乳腺基底样ILC癌细胞异型性大、核级高、核分裂象多,免疫表型ER、PR及HER2“三阴性”,CK5/6和EGFR阳性,符合基底样亚型,易发生邻近部位和远处组织或器宫转移,对化疗反应差,预后较差.     

乳腺实性乳头状癌73例临床病理诊断

目的对乳腺实性乳头状癌(solid papillary carcinoma,SPC)的临床病理特征和免疫表型特点、预后和鉴别诊断进行探讨。方法收集伴或不伴有浸润癌的SPC共73例,总结其临床资料、大体和组织病理特征,并行透射电镜观察及免疫组织化学EnVision法染色。选用抗体包括CK、肌上皮标记、神经内分泌标记、增殖标记Ki-67和ER、PR、c-erbB-2等。结果本病好发于老年女性,发病平均年龄64.7岁。肿瘤最常见的临床症状为乳腺肿块和乳头溢液。行腋窝淋巴结清扫术43例中有31例检出癌转移。镜检所有标本均见到实性乳头状病变,25例伴有黏液分泌。周边常可伴有导管内乳头状瘤。肿瘤细胞呈多边形、卵圆形或梭形,呈印戒样。胞质丰富,呈嗜酸性或细颗粒状。细胞核轻度或中度异型,51例核分裂象5个/10HPF。43例伴发浸润癌。肿瘤基底型CK表达呈阴性。平滑肌肌动蛋白SMA、p63在乳头轴心肌上皮的阳性率分别为91.8%、67.1%,在导管周围肌上皮的阳性率分别为91.8%,73.9%。CgA和Syn以及NSE阳性率分别为89.0%,86.3%,95.9%。Ki-67平均阳性指数为10.2%。73例行ER、PR染色的肿瘤大部分呈阳性,Her-2大部分呈阴性。电镜下可见到细胞内的神经内分泌颗粒。结论乳腺SPC是一种低度恶性的乳腺导管内癌,好发于老年女性,有其独特的组织形态、免疫组织化学特征,部分SPC与乳腺黏液癌和神经内分泌癌相关。随访资料显示SPC具有良好的预后。     

男性浸润性乳腺癌39例临床病理分析

目的探讨男性浸润性乳腺癌的临床病理学及免疫表型特征。方法回顾性分析39例男性浸润性乳腺癌的临床病理学及免疫表型特征,并复习相关文献。结果 39例男性浸润性乳腺癌患者中年龄最小29岁,最大90岁,中位年龄62岁;左侧20例,右侧19例,占同期乳腺癌患者约0.83%。浸润性导管癌35例,其中3例伴有浸润性微乳头癌成分,2例黏液癌,1例囊内乳头状癌,1例浸润性乳头状癌。按组织学分级:Nottingham 1级8例,2级26例,3级5例。免疫表型:ER阳性36例,占92.3%。PR阳性36例,占92.3%。HER-2阴性37例,HER-2不确定2例,其经FISH检测发现1例有HER-2基因扩增,1例未发现扩增。Ki-67高表达(≥14%)者26例,低表达(14%)者13例。结论男性浸润性乳腺癌少见,以60岁以上老年人多见,ER、PR阳性率高,HER-2阳性率极低。     

雄激素受体在乳腺癌中的表达及其与雌、孕激素受体和HER2的关系

目的 研究雄激素受体(AR)在乳腺浸润性导管癌中的表达及其与雌激素受体(ER)、孕激素受体(PR)和HER2状态的关系,探讨其作为乳腺癌治疗靶点的可行性.方法 采用免疫组织化学EnVision法检测AR、ER、PR、HER2在175例乳腺浸润性导管癌中的表达,依据结果分为腺腔A型、腺腔B型、HER2过表达型和三阴性型(ER-/PR-/HER2-)组.结果 175例中AR阳性88例(50.3%),AR表达与ER、PR、HER2均呈正相关(P＜0.01).腺腔A型53例(30.3%),腺腔B型33例(18.9%),HER2过表达型23例(13.1%),三阴性型66例(37.7%),AR阳性率分别为56.6%(30/53),75.8%(25/33)、47.8%(11/23)和33.3%(22/66),组间AR阳性率差异显著(x2=17.054,P=0.001).三阴性型组AR阳性者核分裂象较少(x2=5.140,P=0.023),腺腔A型组AR阳性者多为年轻患者(x2=4.567,P=0.033),差异有统计学意义.其他组内AR表达与否和临床病理学特征比较无统计学意义.结论 AR在乳腺癌中有较高的阳性率,可作为乳腺癌,特别是三阴性型乳腺癌的治疗靶点.     

雄激素受体在乳腺癌中的表达及其与雌、孕激素受体和HER2的关系

目的 研究雄激素受体(AR)在乳腺浸润性导管癌中的表达及其与雌激素受体(ER)、孕激素受体(PR)和HER2状态的关系,探讨其作为乳腺癌治疗靶点的可行性.方法 采用免疫组织化学EnVision法检测AR、ER、PR、HER2在175例乳腺浸润性导管癌中的表达,依据结果分为腺腔A型、腺腔B型、HER2过表达型和三阴性型(ER-/PR-/HER2-)组.结果 175例中AR阳性88例(50.3%),AR表达与ER、PR、HER2均呈正相关(P＜0.01).腺腔A型53例(30.3%),腺腔B型33例(18.9%),HER2过表达型23例(13.1%),三阴性型66例(37.7%),AR阳性率分别为56.6%(30/53),75.8%(25/33)、47.8%(11/23)和33.3%(22/66),组间AR阳性率差异显著(x2=17.054,P=0.001).三阴性型组AR阳性者核分裂象较少(x2=5.140,P=0.023),腺腔A型组AR阳性者多为年轻患者(x2=4.567,P=0.033),差异有统计学意义.其他组内AR表达与否和临床病理学特征比较无统计学意义.结论 AR在乳腺癌中有较高的阳性率,可作为乳腺癌,特别是三阴性型乳腺癌的治疗靶点.     

乳腺实性乳头状癌伴浸润性癌临床病理分析

目的探讨乳腺实性乳头状癌(solid papillary carcinoma,SPC)伴浸润性癌的临床病理特点、组织学特征和免疫表型。方法收集乳腺SPC伴浸润性癌8例,总结该组病变的临床资料,采用HE及免疫组化En Vision两步法染色检测组织病理学特征。结果乳腺SPC伴浸润性癌好发于老年女性,平均发病年龄55.5岁,其发生率约占SPC总病例的30%。肿瘤最常见的临床特征为乳腺肿块和乳头溢液,伴浸润癌常见的类型为乳腺非特殊类型癌和黏液癌,亦常伴神经内分泌分化。SPC伴浸润性癌时,浸润癌周边及其癌巢内肌上皮染色均为阴性。SPC与伴随的浸润癌区域ER、PR均阳性且阳性率较高(≥70%),HER-2均阴性,Ki-67增殖指数均≤10%。神经内分泌免疫组化标记Cg A及Syn均双阳性或单个阳性。结论 SPC可能是低级别乳头状导管原位癌的变异型,其具有进展为其他类型乳腺浸润性癌的潜能。SPC可能为伴神经内分泌分化乳腺黏液癌及非特殊类型癌原位癌阶段的病变。     

乳腺实性乳头状癌78例临床病理特征

目的探讨乳腺实性乳头状癌(solid papillary carcinoma, SPC)的临床病理学特征及预后。方法采用免疫组化Ventana法对78例乳腺SPC进行检测;采用FISH法对HER-2基因进行检测,并复习相关文献。结果 78例乳腺SPC患者均为女性,平均64.7岁,多以乳头溢液和(或)乳腺肿块就诊。78例中45例为原位SPC,33例伴浸润性癌。2例可见淋巴结转移。免疫表型:ER、PR均强阳性。70例神经内分泌标志物阳性,8例阴性。Ki-67增殖指数为3%～40%。11例原位SPC肌上皮表达缺失。78例患者HER-2基因检测均无扩增。78例患者随访4～64个月,平均17.6个月,均未见肿瘤复发。结论 SPC是一种好发于老年女性的低度恶性乳腺癌,常表达神经内分泌标志物,淋巴结转移率低,预后良好。     

乳腺分泌基质的化生性癌5例临床病理观察

目的探讨乳腺分泌基质的化生性癌(matrix-producing metaplastic carcinoma, MPMC)的临床病理学特征、免疫表型、诊断及鉴别诊断。方法对5例MPMC的临床特征及组织病理学进行观察,采用免疫组化SP法检测CK5/6、EGFR、S-100、p63、ER、PR及HER-2表达,并复习相关文献。结果 5例女性乳腺癌患者,年龄32～62岁(平均51岁),3例病灶位于左侧,2例位于右侧,肿物呈结节状、膨胀性生长,边界较清,最大径1.4～3.5 cm。镜下见浸润性癌成分直接向黏液软骨样基质过渡,含黏液软骨样的基质与瘤细胞形成结节状,结节具有外周型和弥漫型两种生长模式,瘤细胞较小或呈多角形、梭形,核圆形或卵圆形,胞质较少。免疫表型:S-100阳性,CK5/6、EGFR大部分阳性,ER、PR、HER-2及p63阴性。5例中4例术后辅以化疗,1例术后未做治疗,目前患者均生存。结论 MPMC属于三阴型乳腺癌,是一种极其罕见的乳腺化生性癌,需要与形态相似的乳腺肿瘤鉴别,结合特有的镜下形态及免疫组化标记可以明确诊断。     

Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors.

With the increasing incidence of ductal carcinoma in situ (DCIS) of the breast and its relationship to invasive breast carcinoma, it is important to understand the biology of this entity. We report on a hospital-based survey of 219 case subjects with DCIS of the breast without associated invasive carcinoma diagnosed between 1982 and 1994. The cases of DCIS were analyzed for architectural type, size, nuclear grade, necrosis, calcification, periductal fibrosis, neovascularization, estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu expression. Periductal neovascularization was associated with tumor size, microcalcifications, periductal fibrosis, and HER-2/neu overexpression. Expression of ER and PR was observed in 60 and 62% of the cases, respectively, and HER-2/neu overexpression in 28% of the cases. ER and PR expression were both inversely associated with comedo histology and nuclear grade. HER-2/neu overexpression was positively associated with comedo histology, high nuclear grade, and periductal neovascularization and was inversely correlated with both ER and PR expression. High nuclear grade was positively associated with comedocarcinoma, necrosis, microcalcification, and periductal fibrosis. The role of these molecular/pathologic markers in the biology of DCIS and their potential clinical implications are discussed.     

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer

AIMS: To investigate the association between tumour characteristics and HER-2/neu by immunohistochemistry in primary operable breast cancer. METHODS: The association between HER-2/neu and other clinicopathological factors was evaluated in 1362 consecutive patients with primary breast cancer treated between 2000 and July 2003 in one centre. Microscopic tumour size, tumour grade, lymph node status, patient's age, oestrogen receptor (ER), progesterone receptor (PR), and joint ER/PR status were evaluated, using the chi2 test for univariate analysis and logistic regression for multivariate analysis. The hormone receptors and HER-2/neu were studied immunohistochemically. Using the HER-2/neu DAKO scoring system, scores of 0, 1+, or 2+ were defined as negative and 3+ as positive. Data for DAKO scores 2+/3+ versus 0/1+ are also presented. RESULTS: Hormone receptor negative breast cancers were more often HER-2/neu positive than hormone receptor positive cancers, both for ER (28.7% v 6.8%) and PR (19.9% v 5.9%). In multivariate analysis, both ER, PR, and tumour grade were independently associated with HER-2/neu. In ER+ tumours, HER-2/neu overexpression was significantly lower in PR+ than in PR- cases (11.5% v 5.4%). HER-2/neu overexpression (2.7%) was lowest in the large subgroup of ER+PR+ tumours with low tumour grade (grade 1-2), comprising 46.1% of all patients. CONCLUSIONS: ER, PR, and tumour grade are independent predictors for HER-2/neu overexpression in women with primary operable breast cancer. ER and PR are negatively associated with HER-2/neu, whereas tumour grade is positively associated with HER-2/neu. In women with ER+ tumours, PR status also affects the likelihood of HER-2/neu expression.     

Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma

Patients with lymph node-negative breast carcinoma (LNNBC) and positive hormone receptor (HR) status during estrogen-based endocrine therapy have different prognoses. The contribution of HER-2 (human epidermal growth factor receptor-2) has not been extensively evaluated. We stained 230 LNNBCs for estrogen and progesterone receptors (ER and PR) and HER-2. HER-2 gene status was studied in 150 randomly selected tumors by chromogenic in situ hybridization and cases with discordant or nondefinitive results by fluorescence in situ hybridization. Patients with ER+ and/or PR+ tumors were treated with tamoxifen. We found positive expression of ER, PR, and HER-2 in 73.7%, 67%, and 27.8%, respectively, and HER-2 amplification in 18.0%. Poorer outcome was seen for patients with ER+ and/or PR+/HER-2 overexpressing tumors and as a trend for patients with HER-2 amplification. ER/PR and HER-2 expression showed an independent prognostic value. In LNNBCs with positive HR status, HER-2 overexpression and/or amplification confer an aggressive tumor phenotype, and this might be related to tamoxifen unresponsiveness.     

Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast

Androgen receptor has been implicated in the pathogenesis of breast carcinoma. In this study, we explored the potential role of androgen receptor in breast cancer by analyzing its expression using immunohistochemistry and its relationship with tumor progress (ductal carcinoma in situ [DCIS] versus invasive ductal carcinoma [IDC]); nuclear grades (high grade [HG] versus non-high grade); expression of estrogen receptor (ER), progesterone receptor (PR), HER-2; and 3 molecular classifications: cytokeratin classification, triple (ER/PR/HER-2) negative classification, and ER/HER-2 classification in 184 breast carcinomas. We found that (1) lack of androgen receptor expression was associated with HG-IDC and with basal subtypes of HG-IDC, suggesting androgen receptor may play an important role in preventing the invasive transformation in this subgroup of breast carcinoma. (2) HG-IDC and HG-DCIS more frequently expressed androgen receptor than ER (55%-93% for androgen receptor and 18%-30% for ER) and were frequently androgen receptor+/ER- (63% for HG-DCIS and 39% for HG-IDC), which made androgen receptor a possible therapeutic target. (3) One third of HG-IDC was negative for androgen receptor, ER, PR, and HER-2, suggesting that further studies are needed to identify other key molecules for targeted therapy. We purpose that androgen receptor should be routinely measured for breast cancer.     

HER-2、P53、Ki-67、Nm23、ER、PR蛋白在乳腺癌中的表达及临床意义

探讨HER-2、P53、Ki-67、Nm23、ER、PR蛋白在乳腺癌组织中表达的特性,同时分析它们之间的相关性和临床意义.应用SP免疫组织化学法检测73例乳腺癌标本中HER-2、P53、Ki-67、Nm23、ER、PR蛋白的表达,并结合其临床和病理资料进行回顾性分析.HER-2、P53、Ki-67、Nm23、ER、PR...     

Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma.

Tissue microarrays (TMAs) have been commonly used to study protein expression by immunohistochemistry (IHC). However, limited data exist on the validity of using TMAs to study gene amplification. In this study, we evaluated the feasibility of using breast carcinoma TMAs to study HER-2 gene amplification by fluorescence in situ hybridization (FISH). In addition, hormonal receptor status (ER and PR) and HER-2 protein overexpression by IHC were also studied, and results were compared with whole tissue sections. FISH for HER-2 was performed on formalin-fixed paraffin-embedded tissue from 114 invasive breast carcinomas both on whole tissue sections and on TMAs containing the same tumors. The TMA was created using 0.6-mm tissue cores with four sampled cores per tumor from the same tissue block used for whole section FISH. The PathVysion HER-2 probe kit was used for the FISH analysis. A ratio of HER-2:Chromosome17 > or =2.0 was interpreted as positive for gene amplification. The ER or PR was interpreted as positive when nuclear staining was detected in more than 10% of tumor cells. The HER-2 IHC (HercepTest; DAKO Corp, Carpinteria, CA) results were interpreted as 0, 1+, 2+, and 3+ according to standard criteria. The FISH results in the TMA and whole sections were concordant in 99 out of 101 successfully analyzed cases (99%). The FISH scores were consistent among the two to four cores in the majority of the cases. ER and PR results were concordant between whole sections and TMA cores in 97% (107/110) and 89% (97/109) cases, respectively. The overall concordance for HER-2 status by IHC between whole sections and TMA cores was 86% (94 out of 109 cases). TMAs are a reliable approach to study HER-2 gene amplification in a high throughput manner.     

Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in invasive breast cancer in women

Introduction

Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) expression are crucial in the biology of breast carcinoma. HER-2/neu gene is amplified and overexpressed in 15-30% of invasive breast cancers. HER-2-positive breast cancers have worse prognosis than HER-2 negative tumors and possess distinctive clinical features. The aim of this study was to assess the expression of HER2 in cancer tissue of patients with invasive breast cancer in correlation with tumor type, histological grade, tumor size, lymph node status, and expression of estrogen receptor and progesterone receptor.

Material and methods

Formalin-fixed, paraffin-embedded tissues from 40 patients with invasive HER-2-positive breast cancer and from 191 patients with HER-2-negative breast cancer were used in this study. HER2 expression was determined using the test HerceptTest™ DAKO.

Results

Among 231 cases of breast cancer, 18 invasive lobular carcinomas and 213 invasive ductal carcinomas were diagnosed. Sixty percent of HER-2-positive breast cancers were ER-positive compared with 77% in the HER-2-negative group (p = 0.002). The expression of PR was observed in 43% of HER-2-positive breast cancers and in 72% of HER2-negative tumors (p = 0.003). Excessive expression of HER2 protein was detected in 60% of patients positive for estrogen receptors, which may worsen prognosis in these patients.

Conclusions

Determination of HER2 overexpression in breast cancer patients, allows for a determination of a group of patients with a worse prognosis.     

Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity.

The protein encoded by the Bcl-2 proto-oncogene has been shown to inhibit programmed cell death and has been primarily studied in hematolymphoid malignancies. Recent work ahs elucidated Bcl-2 expression in nonhematolymphoid malignancies of the lung, prostate, and nasopharynx. Studies of Bcl-2 expression in prostate carcinoma have suggested that its expression may be related to hormonal control. To determine its presence and possible significance in breast carcinoma, a malignancy in which therapy is influenced by hormone receptor status, we used a monoclonal antibody directed against the Bcl-2 gene product to examine Bcl-2 immunoreactivity in a series of paraffin-embedded primary breast tumors. Benign breast tissue showed Bcl-2 positivity in the basal layer and in superficial cells. Twenty-four of 41 (58%) carcinomas were Bcl-2 positive. Staining for Bcl-2 was equivocal in two cases. We identified a strong correlation between Bcl-2 expression and hormone receptor positivity as 23 of 24 (96%) cases that were Bcl-2 positive were estrogen receptor (ER) positive (P = 0.0001) and 21 of 24 (87.5%) were positive for progesterone receptor PR (P = 0.0001). Of 15 Bcl-2-negative cases, 14 (93%) were ER negative and all were PR negative. One case of mucinous carcinoma was ER positive and Bcl-2 negative. Grade 1 and 2 tumors (Scarff-Bloom-Richardson scale) were almost three times as likely to be Bcl-2 positive (90%) as grade 3 tumors (33%) (P = 0.0057). Bcl-2 reactivity appears to be more prevalent in well-differentiated tumors, suggesting that its presence may diminish with loss of differentiation, a hypothesis that is further supported by a subset of cases that were ER negative, Bcl-2 negative, and of poor histological grade. These may be tumors that do not require Bcl-2 inhibition of apoptosis and respond to hormonally independent proliferation factors. Our findings support the hypothesis that Bcl-2 expression may be related to hormonal regulation in breast carcinoma.     

Flow cytometry: a new approach for the molecular profiling of breast cancer

The established method in prognosis of breast cancer includes detection of molecular markers, such as the estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu. These markers are routinely checked via immunohistochemistry (IHC). HER-2/neu is also detected by fluorescent in situ hybridization (FISH). Flow cytometric analysis has not yet been used for detection of such markers. Flow cytometry was performed on four established breast cancer cell lines: MCF7, T47D, BT474, MDA-MB-231, and on one normal breast epithelial cell line: MCF10A. Flow cytometric analysis was used for the detection of ER, PR, HER-2/neu, epidermal growth factor receptor (EGFR), and E-cadherin. Currently, EGFR and E-cadherin are not standard predictive factors in determining survival of breast cancer patients, but both may be beneficial to prognosis. Cells undergoing flow cytometric analysis lost marker expression with increasing passage number. The highest expression was found at cells passaged 0-1 times. MCF7, T47D, and BT474 all had similar marker expression patterns. E-cadherin demonstrated a strongly positive pattern with marker expression of 85-92% among the three cell lines. ER, PR, and HER-2/neu demonstrated a weakly positive expression pattern when compared with E-cadherin. Marker expression ranged from 15 to 61%. These three cell lines were almost negative for expression of EGFR where expression ranged from 0 to 6%. MDA-MB-231 had almost no expression of all 5 markers, with positive values ranging from 0 to 5%. MCF10A had weak positive to almost negative expression values of ER, PR, HER-2/neu, and E-cadherin, which ranged from 3 to 13%. EGFR, both surface and cytoplasmic markers, again were not expressed in MCF10A cells with an expression value of <1%. We found that ER, PR, and HER-2/neu marker expressions in 5 out of 5 cell lines were consistent with established expression patterns. EGFR and E-cadherin expression in 4 out of 5 cell lines were also consistent with established expression patterns. We have shown that flow cytometry provides quantitative data on expression patterns of important prognostic markers in breast cancer.     

TopoⅡα在老年乳腺癌中的表达及其临床病理意义

目的对老年乳腺癌中TopoⅡα的表达与多个临床病理因素行相关性分析,探讨其表达的临床意义。方法应用免疫组化SP法检测南方医科大学附属南方医院近2年来所有老年乳腺癌共105例中TopoⅡα、ER、PR以及HER-2的表达情况;依据免疫组化的表达将其近似划分为LuminalA型(ER+和/或PR+,HER-2-)、LuminalB型(ER+和/或,PR+,HER-2+)、HER-2过表达型(ER-,PR-,HER-2+)和Basal-like型(ER-,PR-,HER-2-)4个分子亚型,对比TopoⅡα表达阳性率的差异。用统计学软件SPSS13.0作为统计分析的工具,TopoⅡα表达与临床病理因子的关系用卡方检验和Spearman相关分析检验。结果老年乳腺癌组织中TopoⅡα蛋白表达阳性率为62.9%,Basal-like型最高,HER-2过表达型仅次之,再次为LuminalB型,LuminalA型最低(P<0.050);阳性表达在不同组织学分期和淋巴结状态患者间差异中有统计学意义且呈正相关(P<0.050)。在不同肿瘤大小患者间差异无统计学意义。结论乳腺癌组织病理检查应根据ER、PR和HER-2的免疫组化结果行分子分型,进一步行TopoⅡα的免疫组化检测,以获得更多的预后信息,进一步指导老年乳腺癌治疗。